Page last updated: 2024-10-27

fenoldopam and Pulmonary Fibrosis

fenoldopam has been researched along with Pulmonary Fibrosis in 1 studies

Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.

Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.

Research Excerpts

ExcerptRelevanceReference
"Idiopathic pulmonary fibrosis (IPF) is the most common fatal interstitial lung disease, with limited therapeutic options."1.62Dopamine receptor agonists ameliorate bleomycin-induced pulmonary fibrosis by repressing fibroblast differentiation and proliferation. ( Liu, J; Miao, K; Mou, Y; Pan, T; Wang, Q; Xiong, W; Xu, Y; Yu, J, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Mou, Y1
Liu, J1
Pan, T1
Wang, Q1
Miao, K1
Xu, Y1
Xiong, W1
Yu, J1

Other Studies

1 other study available for fenoldopam and Pulmonary Fibrosis

ArticleYear
Dopamine receptor agonists ameliorate bleomycin-induced pulmonary fibrosis by repressing fibroblast differentiation and proliferation.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 139

    Topics: Animals; Antibiotics, Antineoplastic; Benzimidazoles; Bleomycin; Cell Differentiation; Cell Prolifer

2021